Patient Safety

Hippocratic AI Launches Polaris 6 Ultra at 7.4T Parameters

Image
Hippocratic AI Launches Polaris 6 Ultra at 7.4T Parameters

Menlo Park – November 02, 2026 -- Hippocratic AI has launched Polaris 6 Ultra, a healthcare language model that runs a 7.4-trillion-parameter safety constellation 1.3 times faster end to end than its predecessor, Polaris 5, as patients experience it.

The company says the model is the first in healthcare to read a patient's emotional state and plan its next sentence while the previous one is still being spoken. Polaris 5 ran at 5.0 trillion parameters.

Polaris 6 Ultra reaches the first sentence in 0.28 seconds against 0.71 to 0.94 for rivals

On byte-identical prompts on a 671B-parameter LLM, Hippocratic AI's serving stack reaches the first sentence in 0.28 seconds. The four fastest commercial providers took 0.71 to 0.94 seconds. Time to first sentence for the LLM stays at 278 milliseconds.

STERIS to Acquire Xodus Medical, Adding OR Consumables

Pittsburgh – October 13, 2026 -- STERIS, a roughly $6 billion-revenue infection prevention provider with 18,000 Associates, has agreed to acquire Pittsburgh-area surgical safety specialist Xodus Medical, adding a portfolio of operating room consumables.

Financial terms were not disclosed in the announcement.

STERIS Targets Double-Digit Growth in Specialty Surgical Products

STERIS President and CEO Dan Carestio said Xodus Medical's portfolio complements and expands the STERIS offering, particularly through consumables used in the operating room. He said the business has demonstrated an ability to grow at double-digit rates, supported by a specialty product portfolio, a steady stream of new products and a highly effective commercial team.

Carestio said the combined company aims to enhance service to customers and create value for STERIS shareholders.

Longer Teprotumumab Interval Cuts Hearing Decline Risk by 60%

Image
Longer Teprotumumab Interval Cuts Hearing Decline Risk by 60%

Los Angeles – October 13, 2026 -- TED patients with pre-existing hearing loss were more than 60% less likely to suffer a further hearing decline when teprotumumab (TEPEZZA) infusions were spaced six weeks apart instead of the standard three, according to a retrospective study presented at the ASOPRS 57th Annual Fall Scientific Symposium.

Hearing decline hit 45% of patients on the standard schedule at 24 weeks

Nine of 20 patients (45%) on the standard three-week schedule showed a clinically significant decline on formal audiometry at 24 weeks. On the six-week schedule, the rate was about one in six. Clinical significance was defined using American Speech-Language-Hearing Association (ASHA) criteria.

The symposium ran October 8-9, 2026, at the Hyatt Regency New Orleans. Shoaib Ugradar, MD, was the presenting author. The study was led by Raymond Douglas, MD, PhD.

DisposeRx CEO Warns Medication Safety Gap Persists After Treatment Ends

Image
DisposeRx CEO Warns Medication Safety Gap Persists After Treatment Ends

Southern Pines, N.C. – – October 03, 2026 -- DisposeRx CEO William Simpson is pressing the healthcare industry to extend medication safety protocols beyond the point of prescribing, arguing that leftover drugs left in home medicine cabinets create unmanaged risk once a treatment course concludes.

Simpson says current safety standards stop short of covering the full prescription life-cycle.

In a new commentary, Simpson questions whether the same rigor applied when a patient begins therapy is matched when a condition improves, a dosage changes, one medication replaces another, a physician deprescribes a no-longer-necessary therapy, an antibiotic course ends, or a patient is discharged from the hospital with an altered regimen.

Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Image
Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Palo Alto, Calif. – October 01, 2026 -- TurnCare, Inc. reported a 36.2% reduction in total hospital-acquired pressure injuries (HAPIs) among ECMO patients following implementation of its GuardianTM System, according to new clinical data presented at the 37th Annual Extracorporeal Life Support Organization (ELSO) 2026 Conference in Nashville, Tennessee.

Single-center study tracks outcomes across 2,707 ECMO days

The retrospective pre- and post-cohort analysis, conducted at M Health Fairview University of Minnesota Medical Center, compared a baseline group of 317 ECMO patients (327 runs, 2,112 ECMO days) against a Guardian-treated cohort of 92 patients (97 runs, 595 ECMO days). Chris Linke, MHI, RN, CSSMBB, presented the findings.

Leapfrog Group Names Retired Navy VADM Raquel Bono Board Chair

Image
Leapfrog Group Names Retired Navy VADM Raquel Bono Board Chair

Washington – September 25, 2026 -- The Leapfrog Group, a national watchdog organization of employers and other health care purchasers, has elected Raquel Bono, MD, MBA, FACS, as its new Board Chair, marking the first time a surgeon has led the nonprofit's board.

Retired Navy Vice Admiral brings $50 billion health system oversight to Leapfrog's board

Dr. Bono is a board-certified trauma surgeon and retired three-star Vice Admiral in the U.S. Navy, where she served as the 11th Chief of the Navy Medical Corps. From 2015 to 2019, she directed the Defense Health Agency, overseeing integration of a $50 billion global health system serving millions of service members and their families.

Otsuka ICU Medical Recalls Saline Bags Mislabeled as Potassium Chloride

Image
Otsuka ICU Medical Recalls Saline Bags Mislabeled as Potassium Chloride

Austin, Texas – – September 20, 2026 -- Otsuka ICU Medical LLC has issued a voluntary user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL, after discovering that bags labeled as saline may actually contain highly concentrated Potassium Chloride Injection.

Mislabeled overwrap conceals lethal potassium concentrate inside saline packaging

The affected lot, NDC 0990-7984-23, Lot 1042188, carries external labeling identifying it as 0.9% Sodium Chloride Injection, USP. Internally, however, the overwrap may instead contain Potassium Chloride Inj. 10 mEq (NDC 0990-7074-26, Lot 1035181), a highly concentrated formulation intended for diluted use only.

InventHelp Client Unveils Patient Repositioning Device for Licensing

Image
InventHelp Client Unveils Patient Repositioning Device for Licensing

Pittsburgh – September 19, 2026 -- An inventor from Brooklyn, N.Y., has developed a device called NURSES WEEKEND designed to reduce injury risk when repositioning patients in hospital and care beds, according to InventHelp, which submitted the design and is now seeking a manufacturing or marketing partner.

Device targets injury risk in routine patient care tasks

The invention provides a mechanism to move patients in bed for tasks such as changing linens, performing hygiene care, and preventing pressure sores. Its adjustable design is intended to reduce physical strain on medical professionals and caregivers while improving patient comfort and safety.

OnPoint Surgical AR System Hits 1.1mm Spine Screw Accuracy in Peer-Reviewed Study

Concord, Mass. – September 16, 2026 -- OnPoint Surgical's augmented reality navigation system placed pedicle screws with a positional error of 1.1 mm and an angular error of 1.3°, figures 2 to 5 times smaller than those reported for competing navigation and robotic platforms, according to a peer-reviewed study published in the Journal of Spine Surgery.

FARE Launches Anatool, First Point-of-Care Digital Guide for Anaphylaxis

Image
FARE Launches Anatool, First Point-of-Care Digital Guide for Anaphylaxis

Cincinnati – September 16, 2026 -- Food Allergy Research & Education (FARE) has launched Anatool, a digital clinical support tool designed to standardize anaphylaxis recognition and treatment at the point of care for emergency physicians, paramedics, nurses and allergists.

Tool translates international consensus report into bedside guidance

Developed with Tim Dribin, MD, of the Division of Emergency Medicine at Cincinnati Children's, Anatool is built on recommendations from a landmark international consensus report on anaphylaxis published in The Journal of Allergy and Clinical Immunology. Dribin co-chaired that report with Hugh Sampson, MD, of the Icahn School of Medicine at Mount Sinai, and Antonella Muraro, PhD, of the University of Padua.